Those results indicate risks of misdiagnosis using liquid biopsy to detect KRAS mutation in CRC patients, and KRAS testing results from liquid biopsy samples have to be handled carefully and only be used when tissue samples are not available. This evidence concerns the gene KRAS and colorectal carcinoma.